NVCR Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 18.61%, SMA50 8.18%, SMA200 -0.28%). The stock’s 14-day RSI is 58.86 (neutral), while the ATR of 1.21 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -38.34% below its high and over 40.02% above its low. Average 10-day trading volume of 1.04 million shares is below the 3-month average of 1.56 million, indicating normal recent market interest.

Novocure Ltd has 116.45 million shares outstanding. The public float is 96.42 million shares, elevated short interest at 11.77% of float. This equals 10.14 million shares. The short ratio is 5.53 days. Institutional investors hold 96.56% of the float. Insiders own 9.96%. Leonard Frank X holds 459.52 thousand shares, Cordova Ashley has 437.57 thousand shares and DOYLE WILLIAM F has 328.40 thousand shares. Over the past six months, insider transactions show net selling. They sold 54.89 thousand shares across 8 transactions.

Novocure Ltd generated EPS of -$1.61 over the past year. Five-year average earnings growth is -83.87%. Wall Street analysts project EPS growth of 7.48% annually over the next five years. The latest quarter delivered EPS of -$0.13. The next quarter is forecast at -$0.41. Next year's EPS is expected at $3.56. Analyst sentiment is neutral. Analyst rating data shows there are 1 Strong Buy ratings, 6 Buy ratings, 6 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $52.00 to $17.00. The high target offers 238.76% upside. The low target suggests 10.75% downside. The mean target is $31.38. This offers 104.43% upside. Novocure Ltd earnings surprise history is frequent misses against expectations. The quarter that ended July 23, 2026, missed forecasts by -60.79%. The prior quarter beat by 21.05%. Over the last six quarters, Apple has recorded several small beats. These include -34.04% in April 24, 2025.

Novocure Ltd (NASDAQ:NVCR) closed at $15.35 USD, losing -$0.28 (-1.79%) from the previous close of $15.63. The stock is currently mid-range between its 52-week high and low $9.82 and $21.45. With a market capitalization of about $1.79 billion, Novocure Ltd is classified as a small-cap and shows market-like volatility (beta ~1.01). Key stats such as the average daily volume over the past year has been around 1.58 million shares, in line with its 52-week average. Headquartered in Baar, None, Novocure Ltd operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Frank Leonard, the company employs approximately 1,605 people and listed since October 02, 2015. NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally.

Novocure Ltd last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$7.95. This means the shares are trading below this model’s fair value.

Novocure Ltd trades at a P/E ratio of -11.92, slightly below the S&P 500 average, with a price-to-sales ratio of 2.58 and a price-to-book ratio of 5.32 trading at moderately above to book value. The P/FCF stands at -85.41, also below market averages.

Our AI price prediction model suggests that Novocure Ltd stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.69%, with price expected at $16.07 by September 24, 2026, within a range of $14.82 to $17.19 3-Month Outlook: Projected rise of 64.63%, reaching $25.27 by December 09, 2026, with a range of $24.76 to $25.79. 1-Year Outlook: Projected loss of -2.08%, with price at $15.03 by September 10, 2027, within a range of $12.65 to $17.29.

Novocure Ltd (NASDAQ:NVCR) shares are flat 0.66% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Novocure Ltd trading at a premium to the broader market with a P/E of -11.92. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $65.45, suggesting 326.38% upside. Our AI forecast model points to short-term strength (4.69% over two weeks), a medium-term rise (64.63% over three months), and a longer-term loss (-2.08% over one year), with expected trading ranges indicating moderate volatility.